Immatics and Editas to Combine Technologies in Collaboration Agreement

Immatics and Editas Medicine have entered into a collaboration and licensing agreement to combine gamma-delta T-cell adoptive cell therapies and gene editing to develop cancer treatments.

Under the agreement, Immatics gains non-exclusive rights to Editas’ CRISPR gene editing technology for use with its own cell therapy platform based on gamma-delta T-cells. The goal of the collaboration is to redirect gamma-delta T-cells to target cancer cells.

Engineered cell therapies “have the potential to significantly impact the treatment paradigm for cancer,” said Rainer Kramer, chief business officer at Immatics.

The financial terms of the deal were not disclosed.